Liraglutide: once-daily GLP-1 agonist for the treatment of Type 2 diabetes. J Clin Pharm Ther. 2011;36:260-74.Ryan GJ, Hardy Y. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes. Journal of clinical pharmacy and ther- apeutics. 2011;36(3):260 -274....
once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults J van Can1, B Sloth2, CB Jensen2, A Flint2, EE Blaak1 and WHM Saris1 INTRODUCTION: Mechanisms for liraglutide-induced weight loss are poorly understood....
Dose‐dependent effects of the once‐daily GLP‐1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double‐blind, placebo‐controlled trial[J] . R. E.Ratner,J.Rosenstock,G.Boka.Diabetic Medicine . 2010 (...
Pfizer announced early Thursday morning that it has selected its preferred once-daily modified release formulation of danuglipron, a move that it said was a significant milestone in the obesity drug’s development. Danuglipron, an oral glucagon-like peptide-1 (GLP-1) recept...
Pfizer announced early Thursday morning that it has selected its preferred once-daily modified release formulation of danuglipron, a move that it said was a significant milestone in the obesity drug’s development. Danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor...
The most advanced of them, danuglipron, has demonstrated good efficacy in a twice-daily formulation, and we believe a once-daily formulation has the potential to have a competitive profile in the oral GLP-1 space," said Mikael Dolsten, MD., PhD., Chief Scie...
CAMBRIDGE, Mass.,Jan. 10, 2025/PRNewswire/ -- Regor Therapeutics Group ("Regor"), a privately-held clinical-stage global biopharmaceutical company, announced topline results from its Phase 2a clinical ...
PARIS, September 20, 2010 /PRNewswire/ -- Sanofi-aventis announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were...
Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity. The aim of the present studies was to design a once weekly GLP-1 analogue by increasing albumin affinity and secu...
INDIANAPOLIS,June 23, 2023/PRNewswire/ --Eli Lilly and Company(NYSE: LLY) announced today new phase 2 data for orforglipron, its first nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist being studied for chronic weight management in participants with obesity or...